Potassium channel modulatory factor 1 (KCMF1) was found upregulated in a differential screen in the metaplastic epithelium in the pancreas of transforming growth factor (TGF)-a transgenic mice. Expression analysis indicated broad overexpression in human cancer tissues. Therefore, we investigated the hypothesis that KCMF1 promotes metaplastic changes and tumor development. KCMF1 represents an evolutionarily highly conserved protein with a 95% identity between human and zebrafish. KCMF1 is expressed during embryonic development and in the majority of adult tissues investigated. Upregulation of nuclear KCMF1 expression is evident in preneoplastic lesions and in several epithelial malignancies, such as pancreatic cancer in mice and humans. In cell culture and in the chicken chorioallantoic membrane model, KCMF1 enhances proliferation, migration and invasion of HEK-293 and Panc1 cells. In crossbreeding experiments, KCMF1-knockdown gene trap mice showed a reduced number and size of premalignant lesions and absence of pancreatic cancer formation in TGF-a transgenic mice. This effect is related to the decreased expression of G1 to S cell-cycle regulators such as cyclin D and cyclin-dependent kinase (CDK) 4. Our data support the hypothesis that KCMF1 mediates pro-oncogenic functions in vitro and in vivo and downregulation of KCMF1 results in the inhibition of pancreatic cancer formation in mice. These effects are mediated through downregulation of cell-cycle control genes such as cyclin D and CDK4.
Introduction
Pancreatic cancer is one of the leading causes of cancer deaths in the Western world (Ghaneh et al., 2006) . Recent study led to important advances in our understanding of the tumor biology underlying this devastating disease. In our current understanding, a sequence of genetic alteration finally leads to pancreatic cancer. This stepwise process is reflected in the histological, preneoplastic changes, which are summarized in the pancreatic intraepithelial neoplasia (PanIN) model of pancreatic cancer. PanINs encompass a spectrum of pancreatic ductal epithelial changes characterized by enhanced mucin production, graded nuclear atypia and loss of cell polarity (Hruban et al., 2001) . However, the early metaplastic changes, cellular origin of pancreatic cancer and the molecular cascades involved in metaplastic changes remain under investigation (Maitra and Hruban, 2008) .
At the molecular level, several genes are implicated in the progression of pancreatic cancer. These genes include kRas, INK4A/ARF and TP53 and the epidermal growth factor, transforming growth factor (TGF)-b, Notch and hedgehog signaling pathways (Jaffee et al., 2002; Miyamoto et al., 2003; Thayer et al., 2003) . Activating kRas mutations are present in virtually all human ductal pancreatic cancers. In addition to the activation of kRas, the tumor-suppressor loci p53, INK4a and SMAD4 are frequently inactivated in human pancreatic cancer (Almoguera et al., 1988; Barton et al., 1991; Caldas et al., 1994; Hahn et al., 1996) . This leads to enhanced cell-cycle progression as the hallmark of malignant transformation and the progression of preneoplastic lesions. Cell-cycle progression is regulated by cyclin-dependent kinase (Cdk) complexes. D-type cyclins interact with Cdk4 and Cdk6 to control the progression through G1 phase (Sherr and Roberts, 1999) . D-type cyclins and the catalytic subunits, Cdk4/6, assemble into active complexes during early G1, followed by the activation of cyclin E-Cdk2 complexes during late G1 phase (Johnson et al., 1993) . Cyclin D1 belongs to the highly conserved cyclin family, members of which are characterized by a sequential expression throughout the cell cycle. Mutations, amplification and overexpression of the cyclin D1 gene,CCND1, are observed in a variety of tumors and may contribute to tumorigenesis (Gillett et al., 1996; Hall and Peters, 1996; Yamamoto et al., 2006; Molenaar et al., 2008) .
Animal models of pancreatic cancer have been established over the last decade, which reflect the morphological and molecular features of the PanIN model of pancreatic cancer progression. Transgenic mice overexpressing TGF-a under the control of the rat elastase promoter develop a massive fibrosis and metaplasia of acinar to ductal cells in the pancreas. This metaplastic epithelium represents premalignant lesions that progress to invasive cancer after the acquisition of additional genetic alterations (Wagner et al., 1998b; Wagner et al., 2001) . In these premalignant lesions, the cell-cycle progression is induced, but the S-phase entry is blocked, as the cell-cycle control genes such as p21/Cip1 through the p53 pathway are upregulated. Consequently, malignant transformation is accelerated after genetic inactivation of TP53, indicating a strong selective pressure for loss of functional TP53 in this model (Wagner et al., 2001) .
In a different model of pancreatic cancer, the tissuespecific expression of a mutated kRas (kRasG12D) also results in preneoplastic changes and pancreatic cancer development recapitulating the PanIN model. Pdx1 or p48-Cre-directed expression of mutated kRAS under the control of an endogenous promoter lead to the formation of PanIN lesions and to invasive pancreatic cancer after the age of 7 months (Hingorani et al., 2003; Aguirre et al., 2003) . Crossbreading these mice with strains having genetically defined defects in the tumorsuppressor genes strengthens the PanIN model of pancreatic cancer progression.
Potassium channel modulatory factor 1 (KCMF1) encodes for a zinc-finger protein with hitherto barely characterized function. KCMF1 was mentioned in 2001 at NCBI as an expressed sequence tag clone potentially involved in the regulation of potassium channels in Aplysia californica (http://www.ncbi.nlm.nih.gov; unpublished data, Solomon DH). A partial expressed sequence tag sequence of KCMF1 was identified as a differentially regulated gene during kidney tubulogenesis in vitro and designated as developing branching tubulogenesis 91 (Debt91) (Li et al., 2003) . In addition, KCMF1 was shown to be downregulated in Ewing's sarcoma cell lines after overexpression of CD99 (Kreppel et al., 2006) and upregulated through fibroblast growth factor (FGF) receptor2 signaling pathways in gastric cancer cells and was consequently named basic FGF induced in gastric cancer (Jang, 2004) .
In this study, we show that the nuclear zinc-finger protein KCMF1 is overexpressed in epithelial cancers and especially in pancreatic cancer of mice and human. KCMF1 enhances proliferation, migration and invasion. Downregulation of KCMF1 in vivo reduces preneoplastic changes in the TGF-a transgenic pancreatic cancer model.
Results
The overexpression of TGF-a under the control of the elastase promoter results in a progressive metaplasia of acinar to ductal cells, which represents premalignant lesions in this murine model of pancreatic cancer (Wagner et al., 2001) . In a genome-wide screen, we compared mRNA expression patterns of TGF-a transgenic (Wagner et al., 1998b) , amphiregulin transgenic (Wagner et al., 2002) and littermate control mice at the age of 14, 28 and 180 days to identify genes involved in the formation of these premalignant lesions. This screen resulted in 558 differentially regulated genes (Supplementary Material S1). These genes were scored for (1) regulation in TGF-a transgenic mice as compared with littermates, (2) increased expression as metaplasia progresses and (3) overlap with amphiregulin transgenic mice (Supplementary Material S1). Most prominently, KCMF1 met all the criteria and was therefore analyzed in more detail. With mRNA in situ hybridization we detected high levels of KCMF1 expression in TGF-a transgenic mice starting as early as day 14 postpartum in the metaplastic epithelium with a further increase in the expression in advanced metaplastic changes and in pancreatic cancers arising in this model (Supplementary Material S1 and below). Expression analyses of murine tissues revealed mRNA and protein expression as early as embryonic day 7.5 during development and in the majority of adult tissues investigated (Supplementary Material S2) .
KCMF1 is an evolutionarily highly conserved protein that is organized in 7 exons spanning 57.22 MB region on murine chromosome 6 ( Figure 1a ) and an 88.38 MB region on human chromosome 2. The protein is composed of 381 amino acids with a calculated molecular weight of 42 kDa (Figure 1c) . Sequence comparisons indicate an evolutionarily highly conserved protein, for example, with a homology of 95% between human and zebrafish ( Figure 1d ). Interestingly, even in the placozoan Trichoplax adhaerens a homolog gene of KCMF1 exists with a 37% identity and with a particularly high homology to exon 6.
In silico analyses indicate that KCMF1 protein encodes two N-terminal zinc-finger domains (ZZ-type encoded by exons 1 and 2, followed by a C2H2 type encoded by exon 3), a coiled-coil domain (encoded by exon 6) and a C-terminal proline-rich region (Figure 1c ). Furthermore, a putative nuclear import signal and two leucine-rich nuclear export signals were identified on the basis of sequence analysis (Figure 1b) . KCMF1 is expressed in normal pancreatic ducts and in endocrine cells in the nontransformed pancreas in mice (Figure 2a ). KCMF1 is spatially and temporally overexpressed in the metaplastic epithelium in TGF-a transgenic mice (Figure 2b ). Consequently, we detected high expression levels of KCMF1 in malignant tumors that develop in these mice (Figure 2c) . We evaluated the expression levels in the pancreas of p48-cre/kRasG12D mice as a second model of pancreatic cancer progression in mice (Hingorani et al., 2003) to further strengthen the hypothesis that KCMF1 is upregulated during metaplasia in the pancreas. In the pancreas of p48-cre/ kRasG12D mice, the expression of KCMF1 increased from PanIN I to III lesions. Furthermore, KCMF1 shows a nuclear distribution in the dysplastic epithelium (Figures 2d and e) . Western blot analyses of corresponding tissue lysates confirm the overexpression of KCMF1 in the course of metaplastic changes (Figure 2f ).
To shed light on the expression of KCMF1 in human pancreatic cancer, we performed immunohistochemical staining of pancreatic cancer tissue arrays. In humans, we detected a weak nuclear KCMF1 localization only in 10% of the nontransformed pancreas in a series of more than 100 human pancreatic cancer samples analyzed, (Figure 3a) . In sharp contrast, pancreatic cancer tissues show strong nuclear immunoreactivity of KCMF1 (Figures 3b-d) . Staining of the cytoplasm or combined expression in the cytoplasm and nucleus is only observed in a minority of well-differentiated tumors. Poorly differentiated G4 pancreatic cancer samples show a 100% strong nuclear localization (Figure 3d ). The results observed in this series of pancreatic cancer tissues are summarized in Figure 3e . Clinical data (age, sex and tumor stage) were available for a subset of the analyzed tumor specimen. In this subgroup analyses, we did not observe a correlation of the KCMF1 staining pattern with these clinical characteristics . To analyze whether overexpression of KCMF1 is a general phenomenon in human malignancies, we performed immunohistochemical staining of multiple tissue arrays of human malignancies and the related nontransformed tissues with two independent antibodies. A total of 13 out of 22 malignant tissues show increased KCMF1 expression (Supplementary Material S5). Strong nuclear expression was evident in several adenocarcinomas such as pancreatic cancer, lung adenocarcinoma, ductal breast cancer and prostate cancer, indicating that cancer especially arising from the glands show overexpression of KCMF1.
In vitro, KCMF1 protein is expressed in the majority of cell lines investigated. To gain more insight into the consequence of KCMF1 overexpression, we performed gain-of-function experiments in HEK-293 cells that show only minor KCMF1 expression (Supplementary Material S6A and B) . Overexpression of KCMF1 in HEK-293 cells resulted in a twofold increase of 3H-thymidine incorporation (1.0±0.17 vs 2.07±0.55, Po0.05) as a measurement of proliferation. Migration and invasion of KCMF1-transfected cells were evaluated in Boyden chamber experiments normalized to the difference in proliferation and to the difference in migration. Overexpression of KCMF1 leads to a threefold increase of migration (1.0±0.14 vs 3.28±1.47, Po0.05) as compared with the mock-transfected control. Furthermore, overexpression of KCMF1 resulted in an increase in the number of invading cells (1.0±0.13 vs 1.86 ± 0.46, Po0.05) in these experiments. The results are summarized in Figure 4a .
These data gave a first indication that KCMF1 overexpression refers to a more invasive phenotype in vitro. This hypothesis was further evaluated in vivo in the chorioallantoic membrane (CAM) model. Mocktransfected HEK-293 cells invaded the CAM with a frequency of 33% and formed small tumors under the applied conditions ( Figure 5b ). The average tumor volume for mock-transfected HEK-293 cells was 0.52 ± 1.03 mm 3 . In sharp contrast, KCMF1-overexpressing HEK-293 cells invaded the CAM at a frequency of 83% and formed large, macroscopic tumor nodules ( Figure 5c ). The average tumor volume was significantly increased to 3.93 ± 3.27 mm 3 (Po0.05) in KCMF1-overexpressing HEK-293 cells ( Figure 5d ).
All pancreatic cancer cell lines showed KCMF1 protein expression (Supplementary Material S6). To To follow the expression of KCMF1 in mice and to test the hypothesis that KCMF1 is involved in the formation of premalignant lesions in the pancreas, we aimed to establish KCMF1-deficient mice. The database search identified an embryonic stem cell clone (XE-080) with a gene trap insertion of LacZ in the 5 0 region of KCMF1 (http://baygenomics.ucsf.edu). Sequence analysis and PCR revealed insertion in the first intron of the genomic sequence between exons 1 and 2 of KCMF1, potentially disrupting the first zinc-finger (ZZ-type) of KCMF1 (see Figure 1) . Transgenic mice were generated from this embryonic stem cell clone and further analyzed. Real-time (RT) PCR and subsequent sequencing identified the suspected 5 0 fusion mRNA of the first exon and the LacZ-coding region (data not shown).
Expression pattern analysis of KCMF1 was followed by whole-mount LacZ staining of heterozygote XE-080 animals during embryonic development. As early as e8.5 broad expression of LacZ, indicating KCMF1 expression, was noted. In particular, the developing pancreas, liver, kidney, lungs and the heart show a strong LacZ expression confirming the expression analysis of Immunohistochemical staining detects expression of KCMF1 in the ducts of wild-type mice (a, asterisk) and intense, nuclear staining of the metaplastic epithelium in TGF-a transgenic pancreas (b, arrow). Pancreatic cancers in TGF-a transgenic mice show uniform nuclear KCMF1 expression (c, arrow). Nuclear accumulation of KCMF1 is further evident in the PanIN 1 (d, arrowhead) and PanIN 3 (e, arrowhead) in p48-cre/kRasG12D mice. Western blot analysis shows overexpression of KCMF1, corresponding tissues (a-e) were used for whole tissue extracts.
Original magnification: Â 100; scale bar depicts 50 mm. LacZ/LacZ double-transgenic animals confirmed the temporal and spatial high expression of KCMF1 in the normal ducts and the metaplastic epithelium of TGF-a transgenic mice (Figures 5a-c) . Northern blot, western blot and RT-PCR analyses revealed that the XE-080 gene trap line does not represent a complete knockout but rather a knockdown of KCMF1. Residual expression of KCMF1 is observed due to splicing around the LacZ insertion, which was confirmed by RT-PCR (data not shown). Quantitative RT-PCR detects a reduction of 40% of the wild-type KCMF1 level in the liver of XE-080 line mice (Figure 5d ). This is further confirmed by a reduced level of KCMF1 protein in western blot analyses (Figure 5e ).
The consequences of reduced KCMF1 levels on metaplastic changes in TGF-a transgenic mice were investigated in TGF-a Â XE-080
LacZ/LacZ animals. TGFa Â XE-080
LacZ/LacZ mice were followed for the number and size of the premalignant lesion over 1 year. As expected from the LacZ expression pattern, TGFa Â XE-080
LacZ/LacZ showed reduced levels of KCMF1 expression in the metaplastic epithelium (Figure 5g ) as compared with the TGF-a control (Figure 5f ). The pancreatic wet weight in TGF-a Â XE-080
LacZ/LacZ is reduced to 60% as compared with the TGF-a control animals. Immunostaining with the ductal marker CK19 indicates a reduced number and size of the tubular complexes in TGF-a Â XE-080
LacZ/LacZ mice as compared with the TGF-a control in the pancreas of 6-month-and 12-month-old mice (Figures 5i and h and data not shown). Quantification results show a 55% reduction in the number of tubular complexes in the pancreas of 12-month-old TGF-a Â XE-080
LacZ/LacZ mice (31.66±13.3 vs 17.43 ± 9.39, Po0.05, Figure 5j ). Even more strikingly, these tubular complexes are smaller in size.
Immunostaining with the proliferation marker Ki67 and morphometric quantification reveals 8.4±3.3% Ki67-positive cells in the tubular complexes of TGF-a transgenic mice at the age of 1 year (Figures 6a and c) . The proportion of proliferating ductal cells in the tubular complexes is significantly reduced to 0.67 ± 0.14% in TGF-a Â XE-080
LacZ/LacZ mice ( Figures  6b and c) . In contrast to the TGF-a transgenic mice, we did not observe malignant transformation in TGFa Â XE-080
LacZ/LacZ mice during the observation period. TGF-a transgenic mice showed induction of cell-cycle regulators such as cyclin D and CDK4 in the premalignant lesion as evaluated with immunostaining and western blot analysis (Figures 6d, e and g ). In sharp contrast, this induction of cyclin D1 and CDK4 is strongly reduced in the TGF-a Â XE-080
LacZ/LacZ mice 
Discussion
KCMF1 is an evolutionarily highly conserved zincfinger protein with hitherto undefined molecular function. We found KCMF1 upregulated in preneoplastic lesions in two mouse models of pancreatic cancer progression and in human pancreatic cancer with a predominant nuclear localization. Ectopic overexpression of KCMF1 confers to a more metastatic phenotype in HEK-293 and Panc1 cells. Finally, a mouse line derived from a KCMF1 knockdown embryonic stem cell line reveals a critical function of KCMF1 for the development of preneoplastic lesions in vivo. KCMF1 was originally identified in a differential screen in A. californica; however, the designation 'potassium channel modulatory factor' is somehow misleading. To our best knowledge, we are not aware of any functional or structural evidence that links KCMF1 to potassium channel signaling. In contrast, KCMF1 was identified in several screens to be differentially expressed in tumor cells after either FGF stimulation (here named as basic FGF induced in gastric cancer) (Jang, 2004) or overexpression of CD99 (Kreppel et al., 2006) . Furthermore, it was suggested that KCMF1 (as a partial expressed sequence tag sequence, Debt91) has a central role during kidney branching morphogenesis (Li et al., 2003) . This probable role during kidney development would nicely fit with the early embryonic expression of KCMF1 in the kidney; however, the XE-080 gene trap line does not show major kidney pathology in adult mice. Interestingly, XE-080 mice show a reduced postnatal survival, although the KCMF1 mRNA level is only reduced to 60% compared with the littermates. Our preliminary analyses suggest that this reduced survival is due to delayed lung maturation. This gives a first indication that KCMF1 might be essential for the embryonic development and that a complete lack of KCMF1 might result in embryonic lethality. The final proof of this hypothesis awaits the formal knockout of KCMF1 in mice.
In our current study, we focus on the suggested role of KCMF1 under malignant conditions. Conflicting and preliminary data either suggest a pro-oncogenic (Jang, 2004) or a more tumor-suppressive (Kreppel et al., 2006) function of KCMF1. KCMF1 was identified in both the publications through differential approaches. We identified KCMF1 in a genome-wide differential screen as a protein already upregulated in the very early stages (day 14 postpartum) of metaplastic changes in TGF-a transgenic mice as murine model of pancreatic cancer progression (Wagner et al., 1998a) . Upregulation of KCMF1, here named as basic FGF induced in gastric cancer, was reported in a gastric cancer cell line after basic FGF treatment. TGF-a transgenic mice develop a massive fibrosis in the pancreas that is associated with an overexpression of a variety of growth factors including several members of the FGF family (Wagner et al., 1998b and unpublished results) . Furthermore, overexpression of FGF family members and consequently growth stimulation through FGF signaling pathways is well recognized in human pancreatic cancer (Wagner et al., 1998a; Maitra and Hruban, 2008) . Alogether, these data suggest that FGF signaling pathways are involved in the regulation of KCMF1 in vivo. This regulation of KCMF1 seems to be a general phenomenon, as we observed upregulation of KCMF1 also in the PanIN lesions in p48-cre/kRasG12D mice (Hingorani et al., 2003) and in the epithelial cancers such as breast and prostate cancer. Interestingly, KCMF1 shows a nuclear accumulation under premalignant and malignant conditions in line with the in silico sequence analyses characterizing KCMF1 as nuclear protein.
High KCMF1 mRNA expression levels have been reported to inversely correlate with CD99 abundance in Ewing's sarcoma cell lines. Overexpression of KCMF1 in this setting results in a reduced migration in the Ewing's sarcoma cell line (Kreppel et al., 2006) . In contrast to these publications, we found an enhanced proliferation, migration and invasion after transfection of KCMF1 in epithelial cell lines. This tumor-promoting effect is further supported by the increased invasion and tumor formation in the CAM model in vivo. Furthermore, the temporal and spatial expression of KCMF1 preneoplastic lesions of pancreatic cancer in human and murine carcinoma argues against a tumor-suppressive function of KCMF1 in vivo. The differences between mesenchymal and epithelial tumors could be explained owing to different genetic cascades involved during tumor development (de Alava, 2007; Maitra and Hruban, 2008) . Among these cell lines, we found the upregulation of KCMF1 predominantly in adenocarcinomas, but not in mesenchymal tumors. Furthermore, high levels of CD 99 have been described in pancreatic islets in vivo (Ambros et al., 1991) . This CD 99 expression does not result in the downregulation of KCMF1 under physiological conditions, as we observed pancreatic islets as the side of low-level KCMF1 expression in vivo.
Our hypothesis that KCMF1 promotes tumor progression is further supported by the dramatic decrease in the number and the size of tubular complexes in TGFa Â XE-080
LacZ/LacZ mice. The 40% downregulation of KCMF1 mRNA in XE-080
LacZ/LacZ is sufficient to decrease the number of tubular complexes as the preneoplastic lesion in TGF-a transgenic mice to less than 50%. Even more prominent is that the number of proliferating cells in the metaplastic epithelium reduced Pro-oncogenic function of KCMF1 in pancreatic cancer S Beilke et al from 8% in TGF-a transgenic mice to o1% in TGFa Â XE-080
LacZ/LacZ mice. Induction of the cell-cycle progression represents the hallmark of premalignant metaplasia (Tosh and Slack, 2002) and early pancreatic cancer development in mice (Hingorani et al., 2003; Wagner et al., 2001) . G1-to S-phase progression is tightly regulated through Cdk complexes. In particular, the activity of the cyclin D/CDK4 and CDK6 complex is controlled through transcriptional and post-transcriptional mechanisms and several inhibitors such as the Ink4 protein family and p21/Cip1 (Sherr and Roberts, 1999; Chen et al., 2009; Mendez, 2009) . In this study, we show that the induction of cyclin D and CDK4 and consequently cell-cycle progression through continuous growth factor stimulation is altered in the absence of KCMF1 in vivo.
Our data strongly suggest a tumor-promoting function of the zinc-finger protein KCMF1 in vitro and in vivo. This function places KCMF1 in the line of potential targets in cancer therapy. Further studies are needed to elucidate the molecular function of KCMF1.
Materials and methods

Animals
Transgenic TGF-a mice (Sandgren et al., 1993; Wagner et al., 2001) , LSL-kRas G12D mice (Hingorani et al., 2003) and p48-cre mouse (Nakhai et al., 2007) are described. LSL-kRrasG12D mice were crossed to p48-Cre animals to generate mice with pancreas-specific (p48-kRas) and activate oncogenic kRas (Khasawneh et al., 2009) . The KCMF1-deficient embryonic stem cell line (XE-080) was obtained from Bay Area Functional Genomics Consortium (BayGenomics, Berkeley, CA, USA), injected into 129SV/NMRI male chimeras and mated to C57BL/6J females following standard procedures. Offspring was genotyped with an integration-specific PCR (5 0 -CTTTAGTCATTATTAGGATTGCCTATG-3 0 , 5 0 -TGG GATAGCATTGGAAACGT-3 0 ) and using Southern blot for selected animals.
Histopathological analysis
Tissues were fixed in 4% phosphate-buffered paraformaldehyde, embedded in paraffin, sectioned (4 mm) and stained with hematoxylin and eosin. Immunohistochemical analyses were performed on serial sections of 4 mm as previously described (Wagner et al., 2001) . Paraffin sections were stained with anti-KCMF1 (raised in rabbits against the peptide sequence CTLVREESSSSDEDDR in exon 7, 1:200), anti-KCMF1 (1:200, Sigma-Aldrich, Taufkirchen, Germany and 1:200, Genetex, Irvine, CA, USA), anti-cyclin D (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Ki67, (1:100; Dako, Glostrup, Denmark), anti-Cdk4 (1:100; Santa Cruz Biotechnology) and anti-cytokeratin 19 (1:100, Biozol, Eching, Germany).
Human cancer tissue stainings were performed on AccuMax and Peta tissue arrays A101, A207 (II, III and V), A301 (I and V) (Biomol, Hamburg, Germany) . Human pancreatic cancer tissues (Tissue Microarrays) were stained with two independent antibodies AB-5978 (raised in rabbit against C-terminal peptide of KCMF1 as outlined in the methods) and anti-KCMF1 (Genetex). Furthermore, a third antibody was evaluated for immunohistochemistry (anit-KCMF1 from Sigma) showing a comparable pattern (Supplementary Material S3). Nuclear and cytoplasmatic staining intensity was graded (0 to 3 þ ) and predominant nuclear staining was defined as more intense nuclear labeling and vice versa.
The preneoplastic lesions in TGF-a transgenic mice were quantified on serial sections and random evaluation of at least 50 high power fields were carried out. In parallel, the number of cells in the metaplastic epithelium and the number of Ki67-positive cells was evaluated. Animal groups consisted of at least six per group.
For X-Gal staining of LacZ expression in vivo, tissues were fixed for 60 min in fixing solution (1% paraformaldehyde, 0.2% glutaraldehyde and 0.2% NP-40, 0.01% Na-deoxycholate) followed by immersion in X-gal staining solution (2 mM MgCl 2 , 5 mM K 4 Fe[CN] 6 , 5 mM K 3 Fe[CN] 6 and 1 mg/ml X-gal (5-bromo-4-chloro-3 indoyl-b-D-galactopyranoside)) overnight at 30 1C. Tissues were rinsed in phosphate-buffered saline and postfixed in 4% phosphate-buffered paraformaldehyde.
Quantitative RT-PCR RNA was extracted using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) and first-strand complementary DNA was synthesized using random hexamer primers and superscript II reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA). Quantitative RT-PCR analysis was performed using an ABI PRISM 7700 Sequence Detector System and the SYBR Green PCR Master Mix kit (Applied Biosystems, Wellesley, MA, USA). Specific primers were used in the PCR (KCMF1-Taq-970F: 5 0 -TGAGACGTTCTGCAG GAGGAC-3 0 ; KCMF1-Taq-1125R: 5 0 -TTGTGTTAGTACG CCGGGTTG-3 0 ). To measure mRNA levels of KCMF1, RT-PCR was carried out in triplicates and was normalized to endogenous cyclophilin levels (Wagner et al., 2001) .
RNA in situ hybridization and northern blot analyses A 600-bp RT-PCR fragment of KCMF1 complementary DNA was cloned into the pCR II vector (Invitrogen, Karlsruhe, Germany) and confirmed by sequencing. pCR II-KCMF1 was linearized and gel purified for antisense and sense digoxigenin-labeled riboprobe synthesis (Boehringer Mannheim, Mannheim, Germany). Nonradioactive RNA in situ hybridization was performed on paraffin sections as described by Wagner et al., 2002. Probes of KCMF1 exons 1 þ 2, 3, 6 and 6 þ 7 were amplified by PCR, subcloned into the pCR II-vector, linearized and subjected to radioactive-labeled probe synthesis. Commercial multiple-tissue northern blots were probed according to manufacturer's instructions (Clontech, Palo Alto, CA, USA) and washed at high stringency as described by Wagner et al., 2002. Plasmids and cell culture pCMV-Sport6-KCMF1 was received from RZPD (Berlin, Germany). KCMF1 was cut with EcoRV/XbaI and cloned between the PvuII/NheI restriction sites of the pBI-EGFP vector (Clontech). HEK-293 and Panc1 cell lines were maintained in Dulbecco's modified minimal essential medium (Gibco, Invitrogen Corp., Brooklyn, NY, USA) supplemented with 10% fetal calf serum (Gibco). Cell lines were grown at 37 1C in 5% CO 2 .
Thymidine incorporation, migration and invasion assays In all, 5 Â 10 4 cells were seeded in a 24-well plate incubated with 5 mCi 3 H-thymidine after 24 h for 4 h followed by 30 min in 5% trichloroacetic acid, washed and lysed in 1 N sodium hydroxide. The cell-associated radioactivity was measured by Liquid Scintillation Counter (Pharmacia, Erlangen, Germany).
To quantify the migration and invasion rate of the transfected cells, modified Boyden chamber inserts (pore size of 8 mm, BD Biosciences, Franklin Lakes, NJ, USA) were used. Altogether, 1.5 Â 10 5 cells were seeded in serum-free medium. After 24 h, the migrated or invaded cells were incubated for 15 min with 100 ml CellTiterGlo (Promega, Mannheim, Germany), which analyzes the amount of ATP by DLReady Luminometer (Berthold Technologies, BadWildbad, Germany). Results obtained for migrating and invading cells were normalized to the amount of proliferated cells seeded in parallel.
Western blot
Cells were washed three times in phosphate-buffered saline, pelleted by centrifugation, resuspended in ice-cold CHAPS lysis buffer (10 mM 3{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, 50 mM Tris-HCl, pH 7.8, 150 mM NaCl, 5 mM NaF, 0.5 mM phenylmethylsulfonyl fluoride and protease inhibitors; Complete mix (Roche, Penzberg, Germany)) and cleared by centrifugation. Protein concentrations were determined by the Bradford method (Bio-Rad, Mu¨nchen, Germany). Comparable loading, as well as the protein transfer after blotting, was confirmed through Ponceau S staining and detection of actin as internal control. Proteins were separated on 10% SDS gels, blotted for 1 h, semi-dried and membranes were blocked for 1 h in 5% skim milk. Membranes were incubated with primary antibody overnight at 4 1C, washed twice with TBS-T, incubated with secondary antibody followed by subsequent washing steps and were visualized with ECL (Amersham Biosciences, Freiburg, Germany). Primary antibodies were listed above. Secondary antibodies used were rabbit anti-goat IgG (1:5000; Dianova, Hamburg, Germany), goat anti-chicken IgY-Fc (1:10 000; ICLLAB, Newberg, OR, USA), rabbit anti-mouse IgG (1:10 000; Sigma) and donkey anti-rabbit IgG (1:5000; Amersham Biosciences).
CAM assay CAM assay was carried out as previously described by Kuefer et al., 2004. Briefly, 10 6 HEK-293 cells were resuspended in 50 ml serum-free medium and implanted on fertilized chicken eggs on day 8 of incubation using a silicone ring of 6 mm in diameter. Tumors were sampled with the surrounding CAM 4 days after seeding, fixed in 4% paraformaldehyde, paraffin embedded, cut in 5-mm sections and analyzed by light microscopy. The volume of invaded cells was evaluated on serial sections separated by 40 mm through the whole CAM and the tumor area was evaluated for each section.
Statistical analyses
Proliferation, migration, invasion, tumor volume (CAM model) average number of tubular complexes and ki-67 labeling were expressed as mean and s.d. Differences were evaluated for statistical significance by the Mann-WhitneyWilcoxon test. A P-value o0.05 was considered significant.
